Propionic Acidemia clinical trials at University of California Health
2 research studies open to eligible people
Showing trials for
Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study
open to eligible people ages 1 year and up
The main purpose of this study is to evaluate the long-term safety of mRNA-3927 administered to participants with propionic acidemia (PA) who have previously participated in Study mRNA-3927-P101 (NCT04159103).
at UCLA
mRNA-3927 in Participants With Propionic Acidemia
open to all eligible people
This First-in-Human (FIH) Phase 1/2 study is designed to characterize the safety, tolerability, and pharmacological activity (as assessed by biomarker measurements) and to determine the optimal dose of mRNA-3927 in participants with genetically…
at UCLA
Our lead scientists for Propionic Acidemia research studies include Gerald S. Lipshutz, MD.
Last updated: